TITLE

Do sulfonylurea drugs increase the risk of cardiac events?

AUTHOR(S)
Bell, David S. H.
PUB. DATE
January 2006
SOURCE
CMAJ: Canadian Medical Association Journal;1/17/2006, Vol. 174 Issue 2, p185
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article comments on a study regarding the effect of sulfonylurea drugs on the risk of cardiac events. The death rates of patients taking sulfonylurea drugs is compared with those who managed their diabetes with diet alone or with insulin. The finding of animal studies on the effects of glipizide and glyburide is mentioned.
ACCESSION #
19383913

 

Related Articles

  • All-cause death significantly higher with glibenclamide vs gliclazide.  // Reactions Weekly;11/7/2009, Issue 1277, p2 

    The article focuses on a study which compared the mortality rates associated with the use of glibenclamide and gliclazide for type 2 diabetes mellitus (T2DM). The study compared the all-cause mortality and cardiovascular death rates between 21,731 patients treated with glibenclamide and 3,630...

  • Risk of CV disorders with insulin or sulfonylureas.  // Reactions Weekly;10/4/2008, Issue 1222, p3 

    The article reports on the results of a study on the association between serious ischemic cardiac outcomes and medications used to treat diabetes. Results showed that the use of insulin or sulfonylureas appeared to be linked with an increased risk of ischaemic cardiovascular disorders in...

  • Derivation and Validation of a Prediction Score for Major Coronary Heart Disease Events in a U.K. Type 2 Diabetic Population. Donnan, Peter T.; Donnelly, Louise; New, John P.; Morris, Andrew D. // Diabetes Care;Jun2006, Vol. 29 Issue 6, p1231 

    OBJECTIVE -- To derive and validate an absolute risk algorithm for major coronary heart disease (CHD) events in the U.K. population with type 2 diabetes. RESEARCH DESIGN AND METHODS -- A population cohort with type 2 diabetes was constructed in Tayside, Scotland, U.K., and longitudinally...

  • Thiazolidinediones experience.  // WHO Drug Information;2003, Vol. 17 Issue 2, p92 

    Reports that the Australian Drug Reactions Advisory Committee has received 44 reports associated with rosiglitazone and 28 reports involving pioglitazone. Thiazolidinediones, a class of oral antidiabetic drugs, which act on the peroxisome proliferator activated gamma nuclear receptor to reduce...

  • Transferring the Basal Component of Basal-Bolus Therapy from NPH Insulin to Insulin Detemir Improves Glycemic Control and Reduces Hypoglycemia and Bodyweight in Type 1 and 2 Patients: 6-Month Results from PREDICTIVEâ„¢. Sreenan, Seamus; Aczel, Stefan; Merilainen, Markus; Virkamaki, Antti // Diabetes;Jun2007 Supplement 1, Vol. 56, pA557 

    The article focuses on the findings of PREDICTIVE, a multinational, observational study that aims to determine the safety and efficiency of insulin detemir on patients from 6 European countries. It notes that transferring to detemir significantly improved glycemic control and significantly...

  • Long-term oral nitrate therapy is associated with adverse outcome in diabetic patients following elective percutaneous coronary intervention.  // Cardiovascular Diabetology;2011, Vol. 10 Issue 1, p52 

    The article offers information on the research conducted by the authors related to the association of long-term oral nitrate therapy with adverse outcome in diabetic patients following elective percutaneous coronary intervention (PCI). It states that the study aimed to assess the impact of...

  • Thiazolidinediones and Cardiovascular Risk -- A Question of Balance. Erdmann, Erland; Charbonnel, Bernard; Wilcox, Robert // Current Cardiology Reviews;2009, Vol. 5 Issue 3, p155 

    Background: Several recent meta-analyses of adverse event data from randomized controlled trials with rosiglitazone reveal a possible association between this thiazolidinedione and an increased risk of ischemic myocardial events. This has led to debate on the overall clinical benefit of...

  • Effects of Thiazolidinediones Beyond Glycaemic Control. Kalaitzidis, Rigas G.; Sarafidis, Pantelis A.; Bakris, George L. // Current Pharmaceutical Design;2/11/2009, Vol. 15 Issue 5, p529 

    The incidence of type 2 diabetes continues to increase in the western world over the past decade. Consequently, complications of this disease have reached crisis proportions. In addition to the classical oral hypoglycaemic agents, i.e. sulfonylureas, newer classes have emerged that work by...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk.  // Clinical Cardiology Alert;Jul2007, Vol. 26 Issue 7, p1 

    The article reports that rosiglitazone or Avandia from GlaxoSmithKline will receive a black box warning from the U.S. Food and Drug Administration (FDA) due to concerns over heart failure associated with its use. Another drug called pioglitazone or Actos will also be subject to the warning for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics